Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ulotaront. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 known ✓ | Q96RJ0 | 12/20 | 0.84 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.84 |
| ▸ | DRD2 | P14416 | 1/20 | 0.84 |
| ▸ | HTR7 | P34969 | 1/20 | 0.84 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ulotaront SCHEMBL21273314 | 1.00 | TAAR1 (0.84) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| Ulotaront SCHEMBL21273317 | 0.92 | TAAR1 (0.74) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| Ulotaront SCHEMBL21273309 | 0.90 | TAAR1 (0.97) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| Ulotaront SCHEMBL28517004 | 0.90 | TAAR1 (0.97) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| Ulotaront SCHEMBL21273308 | 0.90 | TAAR1 (0.97) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| Ulotaront SCHEMBL21273312 | 0.90 | TAAR1 (0.97) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| Ulotaront SCHEMBL21273310 | 0.90 | TAAR1 (0.71) | TAAR1HTR1ADRD2HTR7ALDH1A1 | |
| Ulotaront SCHEMBL21273311 | 0.90 | TAAR1 (0.71) | TAAR1HTR1ADRD2HTR7ALDH1A1 | |
| Ulotaront SCHEMBL21273313 | 0.85 | TAAR1 (0.76) | TAAR1HTR1ADRD2HTR7ALDH1A1 | |
| Ulotaront SCHEMBL21273319 | 0.81 | TAAR1 (0.70) | TAAR1HTR1ADRD2HTR7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125393-A1 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2026-05-07 | — | — | US | claimed |
| US-20240425516-A1 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-12-26 | — | — | US | claimed |
| CN-112135827-A | Salts, crystalline forms and methods for preparing the same | 赛诺维信制药公司 | 2020-12-25 | — | — | CN | claimed |
| EP-3752508-A1 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2020-12-23 | — | — | EP | claimed |
| WO-2019161238-A1 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2019-08-22 | — | — | WO | claimed |
| US-20190256525-A1 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-08-22 | — | — | US | claimed |
| US-20260125393-A1 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20240425516-A1 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-12-26 | — | — | US | disclosed |
| US-11987591-B2 | Salts, crystal forms, and production methods thereof | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| CN-112135827-B | Salt, crystal forms and preparation method thereof | 赛诺维信制药公司 | 2024-01-12 | — | — | CN | disclosed |
| US-20220402937-A1 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-12-22 | — | — | US | disclosed |
| US-11440921-B2 | Salts, crystal forms, and production methods thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2022-09-13 | — | — | US | disclosed |
| US-20210053983-A1 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2021-02-25 | — | — | US | disclosed |
| CN-112135827-A | Salts, crystalline forms and methods for preparing the same | 赛诺维信制药公司 | 2020-12-25 | — | — | CN | disclosed |
| EP-3752508-A1 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10815249-B2 | Salts, crystal forms, and production methods thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2020-10-27 | — | — | US | disclosed |
| WO-2019161238-A1 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| US-20190256525-A1 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815249-B2 | Salts, crystal forms, and production methods thereof | TPMT, HNMT, NT5C3B | TAAR1 847/4885HTR1A 121/4885DRD2 306/4885 |
| US-20260125393-A1 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | TPMT, HNMT, RAB35 | TAAR1 1484/4885HTR1A 90/4885DRD2 295/4885 |
| US-20220402937-A1 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | TPMT, HNMT, NT5C3B | TAAR1 847/4885HTR1A 121/4885DRD2 306/4885 |
| US-20240425516-A1 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | TPMT, HNMT, NT5C3B | TAAR1 847/4885HTR1A 121/4885DRD2 306/4885 |
| US-11987591-B2 | Salts, crystal forms, and production methods thereof | TPMT, HNMT, NT5C3B | TAAR1 847/4885HTR1A 121/4885DRD2 306/4885 |
| US-20190256525-A1 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | TPMT, HNMT, NT5C3B | TAAR1 847/4885HTR1A 121/4885DRD2 306/4885 |
| US-11440921-B2 | Salts, crystal forms, and production methods thereof | TPMT, HNMT, NT5C3B | TAAR1 847/4885HTR1A 121/4885DRD2 306/4885 |
| US-20210053983-A1 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | TPMT, HNMT, NT5C3B | TAAR1 847/4885HTR1A 121/4885DRD2 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.